Oculis (NASDAQ:OCS) Sets New 12-Month High – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $30.68 and last traded at $29.56, with a volume of 262308 shares trading hands. The stock had previously closed at $29.63.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on OCS shares. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Stifel Nicolaus boosted their target price on Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Oculis in a report on Tuesday, November 11th. HC Wainwright lifted their price target on shares of Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, JPMorgan Chase & Co. started coverage on Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Oculis Stock Down 0.2%

The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -11.73 and a beta of 0.28. The firm has a 50-day moving average of $25.06 and a two-hundred day moving average of $21.07.

Institutional Trading of Oculis

Several institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its stake in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares during the period. Aventura Private Wealth LLC acquired a new stake in Oculis during the fourth quarter valued at approximately $80,000. Millennium Management LLC bought a new stake in shares of Oculis in the 4th quarter valued at approximately $312,000. Bosun Asset Management LLC acquired a new position in shares of Oculis in the 2nd quarter worth approximately $378,000. Finally, Marshall Wace LLP acquired a new position in shares of Oculis in the 2nd quarter worth approximately $393,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.